Inflexion sells Pharmaspectra to IQVIA for USD 100m

The deal was valued at USD 100m, according to a source familiar with the situation. 

The GP said it increased the company's client base by 160% over three years by investing in sales, marketing and client services. Inflexion added that it also supported market entry into China and the build-out of the team in India. 

Inflexion acquired Pharmaspectra in 2019 via Enterprise Fund IV, which has been fully deployed since the end of that year. The fund invested tickets of GBP 10m-GBP 20m.

The exit is Inflexion's fourth from that fund, following Goals Soccer Centre, Halo Technology, and Virgin Experience Days. 

Inflexion has made nine exits to date in 2022 with a combined valuation of GBP 2.5bn, it said in a statement. 

The GP closed its latest enterprise fund Fund V in May 2019 at GBP 400m. 

People 

Inflexion - Ben Long (partner), Saloshnee Nightingale (assistant director) and Andrea Johnson (investment executive).

Pharmaspectra - Jez Moulding (CEO).

Company
Pharmaspectra hosts a continuously updated and integrated online repository of disseminated medical science information. This includes 16m meeting presentations, 28m publication abstracts, and 417,000 clinical trial results. This data is used across the pharmaceutical sector in which Pharmaspectra has an expansive and diverse customer base, including 13 of the top 20 pharma companies.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Exits
• GPs
• Inflexion Private Equity